Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Olson

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Haematologica|August 8, 2015
Better allele-level matching improves transplant-related mortality after double cord blood transplantationBetül Oran, Kai Cao, Rima M Saliba, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study ResultsPartow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
American Journal of Hematology|February 5, 2024
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II studySairah Ahmed, Qaiser Bashir, Roland L Bassett, et al.
Transplantation and Cellular Therapy|May 9, 2021
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled TrialSairah Ahmed, Qaiser Bashir, Roland Bassett, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2016
Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipientsAla Abudayyeh, Amir Hamdi, Maen Abdelrahim, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Transplantation and Cellular Therapy|June 6, 2022
Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?Rohtesh S Mehta, Rima M Saliba, Eiko Hayase, et al.
Transplantation and Cellular Therapy|May 5, 2022
Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Sassine Ghanem, et al.
Anticancer Research|November 28, 2008
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoJoann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Haematologica|August 8, 2015
Better allele-level matching improves transplant-related mortality after double cord blood transplantationBetül Oran, Kai Cao, Rima M Saliba, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study ResultsPartow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
American Journal of Hematology|February 5, 2024
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II studySairah Ahmed, Qaiser Bashir, Roland L Bassett, et al.
Transplantation and Cellular Therapy|May 9, 2021
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled TrialSairah Ahmed, Qaiser Bashir, Roland Bassett, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2016
Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipientsAla Abudayyeh, Amir Hamdi, Maen Abdelrahim, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Transplantation and Cellular Therapy|June 6, 2022
Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?Rohtesh S Mehta, Rima M Saliba, Eiko Hayase, et al.
Transplantation and Cellular Therapy|May 5, 2022
Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Sassine Ghanem, et al.
Anticancer Research|November 28, 2008
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoJoann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, et al.
Pageof 8